Short answer: Yes. Liver disease can change whether a treatment is suitable, whether it needs to be delayed, and what monitoring is required. It does not automatically rule you out. For elective cell procedures, active liver inflammation, complications of cirrhosis, or an unexplained liver mass need assessment first. Stable mild disease still requires an individual review of liver function and the exact treatment; normal liver tests alone are not clearance.
This article is general information only and is not personal medical advice. If you have liver disease and are considering cell-related treatment in Japan or elsewhere, bring recent liver records to the consultation and follow the advice of your own treating team.

How Liver Disease Affects Eligibility
This guide focuses on elective cell-related procedures, including services offered in Japan. It is not an eligibility rulebook for all medicines, surgery, cancer treatment, or transplantation. For any proposed treatment, ask which part of your liver disease changes the decision: ongoing inflammation, reduced liver function, a complication, or an unresolved diagnosis.
Liver testing can include ALT and AST, ALP and GGT, bilirubin, albumin, and total protein; prothrombin time (PT) measures how long a blood sample takes to clot. The tests ordered vary. Results help assess injury or function, but usually cannot identify the disease by themselves. Your clinician interprets the pattern alongside symptoms, medicines, and earlier results Liver function tests.
Cirrhosis is long-term scarring of the liver. Complications can include fluid in the abdomen (ascites), bleeding from enlarged veins, confusion related to toxin buildup (hepatic encephalopathy), jaundice, and infection. Decompensated cirrhosis means complications have developed; it is not simply another name for a raised liver enzyme Cirrhosis Cirrhosis.
An isolated abnormal result may need repeat testing, including after a recent illness Liver function tests. Do not use an ALT or AST value from another clinic’s website as your own pass-or-fail threshold. The sources cited here do not establish a universal liver-enzyme cutoff or complication rate for all cell products and routes.
Why Clinics May Delay Treatment
Clotting and Bleeding
Cirrhosis can involve bleeding and clotting problems Cirrhosis. If your plan involves liposuction, bone-marrow collection, or an injection, ask how the team will assess the risk for that specific procedure. A clotting-test result should not be treated as a stand-alone eligibility decision.
Patients should request a written peri-procedure plan. The plan should state the PT and platelet values used, the bleeding risk for the planned collection or injection, and which specialist approved continuation or pause of blood thinners. Patients should not adjust these medicines without medical direction (see preparation notes).
Medicines and Sedation
Ask whether collection requires local anesthesia, sedation, or general anesthesia, and who will review your liver records before it is scheduled. Request instructions for your current medicines and the planned pain relief. Do not assume that changing the anesthetic alone makes an otherwise unsuitable procedure safe.
Treatment Burden
Eligibility means something different for a transplant and for a private-clinic injection. Blood-forming stem cell transplantation for certain cancers and blood disorders restores blood-forming cells after high-dose therapy and includes organ and infection checks. This procedure differs from an injection offered by a private clinic Stem cell transplant. Evidence for private clinic infusions is different, and safety assessment depends on the exact product, diagnosis, processing, route, and follow-up. The U.S. Food and Drug Administration warns that unapproved regenerative products have been linked to infections, unwanted immune responses, and other serious harms Important patient and consumer information about regenerative medicine therapies. Patients should compare the exact cell type, source, processing, route, dose schedule, and follow-up, and review the evidence for that exact protocol and condition.
Infection Control
Ask the treating team to assess fever or suspected active infection before an elective procedure. Donor screening is a separate requirement. Japan’s handling notice lists hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and HTLV-1 for assessment by history and testing, including serology and nucleic-acid amplification methods. Parvovirus B19 testing applies when necessary. It also calls for testing for cytomegalovirus, Epstein-Barr virus, and West Nile virus when necessary for immunosuppressed recipients T_doc?dataId=00tc9175&dataType=1.
Which Situations Change the Decision
Active Hepatitis or Abnormal Tests
New abnormal liver results, jaundice, dark urine, or abdominal swelling should be discussed with your treating clinician rather than treated as a screening hurdle. Liver tests can help investigate symptoms, follow known disease, or identify medicine effects Liver function tests. Before an elective cell procedure, ask whether the cause has been established and whether further evaluation is needed.
Decompensated Cirrhosis
Ascites, bleeding from enlarged veins, and hepatic encephalopathy are complications of advanced liver disease Cirrhosis. These call for liver-specialist care, not a routine elective-treatment booking. Ask the specialist whether the proposed procedure is appropriate at all. Improvement does not automatically establish eligibility, especially when the benefit of the cell intervention is unproven.
Liver Mass
A new liver mass requires cancer workup before any cell plan, typically imaging such as CT, MRI, or ultrasound with specialist referral. Biopsy is used in selected cases, and staging records tumor size, location, and spread Diagnosis. Transplant or trial options are considered after that staging. A regenerative or cosmetic cell service should not delay proven cancer care.
Clotting or Platelet Problems
Bring your platelet and clotting results, bleeding history, and anticoagulant list to the procedural team. Ask whether they need additional assessment or a different plan before collection or injection. Do not aim to change a laboratory value just to pass screening, and do not stop blood thinners on your own.
Alcohol or Drug-Related Injury
Medicines and alcohol history can affect how liver tests are interpreted Liver function tests. List prescription drugs, supplements, herbal products, and alcohol use accurately. Ask your clinician what needs investigation and when to repeat tests; do not change prescribed treatment to improve screening results.
Positive Infection Tests
A positive infection-screening result needs interpretation: ask which test was positive, what it means, and whether additional testing is required. Do not equate a donor’s exclusion with a recipient’s ineligibility. HBV can spread through blood and other body fluids, and chronic infection can cause cirrhosis and liver cancer About. The U.S. CDC recommends hepatitis B screening at least once for adults and identifies vaccination as the best prevention; this public-health advice is not a cell-treatment eligibility rule About.
Stable Mild Disease
If you have been told you have mild fatty liver or a resolved episode of hepatitis, submit the actual reports rather than just the diagnosis. Ask whether there is evidence of ongoing injury, reduced function, or complications, and whether your proposed treatment has additional restrictions. Stable results support the review; they do not guarantee that you meet the protocol’s criteria.
| Situation | What to clarify before booking | Why |
|---|---|---|
| New abnormal ALT/AST or rising bilirubin with symptoms | Has the cause been investigated? | Liver tests require interpretation with symptoms and history Liver function tests |
| Cirrhosis with ascites, bleeding, or confusion | Does the liver specialist consider the elective procedure appropriate? | These are significant complications, not just abnormal enzymes Cirrhosis |
| Liver mass or suspected cancer | Has diagnostic workup been completed? | Imaging and, in selected cases, biopsy help establish the diagnosis Diagnosis |
| Positive infection result in a proposed donor | Does this result exclude the donor under the applicable criteria? | Donor suitability and recipient eligibility are separate decisions T_doc?dataId=00tc9175&dataType=1 |
| Stable mild findings with normal function | Routine review of actual reports; proceed only if criteria met | Trend and function matter more than the label alone Liver function tests |
Does the Cell Source Change the Rules
Autologous treatment uses your own cells; allogeneic treatment uses another person’s cells. The source changes donor-screening considerations, but it does not replace assessment of the treatment itself. Japan’s notice says that full screening is not necessarily required in the same way when a patient’s own cells are used, while history and testing should be considered to prevent cross-contamination and protect staff T_doc?dataId=00tc9175&dataType=1.
Do not assume that using your own cells removes treatment risks or that every donor-cell procedure requires immunosuppression. Ask what the particular protocol involves. Evidence for blood-forming transplantation cannot be used as proof that a different clinic infusion works for your condition Stem cell transplant Important patient and consumer information about regenerative medicine therapies.
Japan’s regenerative medicine provision-plan framework is distinct from product approval. Ask whether the exact intervention has approval for the proposed indication, is being studied in a trial, or is offered as a private service under a provision plan. Plan filing is not proof of efficacy T_doc?dataId=00tc9175&dataType=1. Trial registration alone does not prove benefit, and PubMed indexing alone does not establish evidence quality.
What Your Eligibility Check Includes
To answer whether liver disease blocks your treatment, the review usually covers liver diagnosis and date, alcohol history, medicines and supplements, prior hepatitis test results and vaccination, prior transfusions, bleeding history, prior anesthesia problems, heart and kidney disease, diabetes, cancer history, and current symptoms. Published indications and contraindications overviews group these factors, but the final decision rests with the treating physician.
Blood work often includes a complete blood count, liver panel with ALT, AST, ALP, bilirubin, and albumin, kidney tests, blood sugar, clotting tests when bleeding is a concern, and infection tests when indicated by the cell source and clinical situation. Physicians order liver tests when liver disease is known or suspected, when prior results were abnormal, or when medicine use can affect the liver Liver function tests.
Ask which reports are needed and how recent they must be. Existing imaging reports and a liver-specialist letter can be included for the treating team’s review. If the team defers a decision, request the reason and a specific reassessment plan rather than assuming that another normal blood test will be enough.
How to Prepare for an Eligibility Review
To get a clear yes-or-no on eligibility, prepare a short timeline with diagnoses, procedures, hospitalizations, and current medicines with doses, plus recent liver labs, hepatitis results, imaging and endoscopy reports noted above, and vaccination records. Alcohol use should be reported honestly, including recent changes, because it affects anesthesia and liver interpretation.
A Practical Review Scenario
If you have one older abnormal liver result and a newer normal result, send both with their dates, units, and laboratory reference ranges. Add a note listing any illness or medicine change between the tests. Ask whether the team needs another test, imaging, or a liver-specialist letter before deciding. This is a preparation example, not a patient case or evidence that normal results make treatment safe.
- Which liver finding affects my eligibility, and is the decision temporary or final for this protocol?
- If treatment is deferred, what needs to change and who will reassess me?
- What collection method and anesthesia are planned?
- Which infection tests are required for me and, if relevant, for the donor?
- Who handles complications and after-hours care?
- What established alternatives exist, and what will follow-up measure?
Ask for these answers in writing before you decide; if the clinic will not provide them in writing, treat that as a stop signal.
Follow the laboratory’s fasting instructions and tell the team about medicines and supplements; do not change prescribed medicines on your own Liver function tests.
Unsure whether liver disease affects your eligibility?
Bring your recent liver labs, imaging, and medication list to a consultation. A physician can then confirm which option, if any, fits your case.
Bottom Line
Liver disease can lead to additional testing, a modified plan, postponement, or a decision not to offer a particular elective cell procedure. Ask for a written explanation of the finding that matters, the criteria being applied, and whether reassessment is possible. Being accepted by a clinic does not by itself establish that a treatment is effective or appropriate.




